Does TRASTUZUMAB DERUXTECAN Cause Myelosuppression? 242 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 242 reports of Myelosuppression have been filed in association with TRASTUZUMAB DERUXTECAN (Enhertu). This represents 9.0% of all adverse event reports for TRASTUZUMAB DERUXTECAN.
242
Reports of Myelosuppression with TRASTUZUMAB DERUXTECAN
9.0%
of all TRASTUZUMAB DERUXTECAN reports
0
Deaths
98
Hospitalizations
How Dangerous Is Myelosuppression From TRASTUZUMAB DERUXTECAN?
Of the 242 reports, 98 (40.5%) required hospitalization, and 10 (4.1%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB DERUXTECAN. However, 242 reports have been filed with the FAERS database.
What Other Side Effects Does TRASTUZUMAB DERUXTECAN Cause?
Death (384)
Off label use (258)
Nausea (251)
Fatigue (186)
Malignant neoplasm progression (171)
Vomiting (140)
Diarrhoea (132)
Interstitial lung disease (130)
Pneumonitis (125)
Metastases to central nervous system (103)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which TRASTUZUMAB DERUXTECAN Alternatives Have Lower Myelosuppression Risk?
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DKST
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DTTB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB EMTANSINE
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-PKRB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-QYYP